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Giant magnetoresistive biosensors 
for real-time quantitative detection 
of protease activity
Sandeep Adem1, Sonal Jain1, Michael Sveiven1, Xiahan Zhou3, Anthony J. o’Donoghue2 ✉ & 
Drew A. Hall1,3 ✉
proteases are enzymes that cleave proteins and are crucial to physiological processes such as digestion, 
blood clotting, and wound healing. Unregulated protease activity is a biomarker of several human 
diseases. Synthetic peptides that are selectively hydrolyzed by a protease of interest can be used as 
reporter substrates of unregulated protease activity. We developed an activity-based protease sensor 
by immobilizing magnetic nanoparticles (Mnps) to the surface of a giant magnetoresistive spin-valve 
(GMR SV) sensor using peptides. cleavage of these peptides by a protease releases the magnetic 
nanoparticles resulting in a time-dependent change in the local magnetic field. Using this approach, 
we detected a significant release of MNPs after 3.5 minutes incubation using just 4 nM of the cysteine 
protease, papain. in addition, we show that proteases in healthy human urine do not release the Mnps, 
however addition of 20 nM of papain to the urine samples resulted in a time-dependent change in 
magnetoresistance. this study lays the foundation for using GMR SV sensors as a platform for real-time, 
quantitative detection of protease activity in biological fluids.
Proteases play an important role in various physiological activities such as food digestion1, wound healing2, 
immune function3, and intracellular protein turnover4. These enzymes cleave between amino acids in proteins 
and peptides and are the largest class of post-translational modifying enzymes in the human proteome5. In can-
cer and neurodegeneration, unregulated proteolysis can occur when excess proteases are present at the site of 
disease or alternatively when the endogenous inhibitors are lacking6,7. Detection and quantitation of proteases in 
biofluids can provide a greater understanding of diagnosis and staging of these diseases8,9. For example, increased 
levels of the prostate-specific antigen (PSA) protease in blood is correlated with prostate cancer. This protease 
is quantified by an enzyme-linked-immunosorbent assay (ELISA)10. However, since proteases are catalytically 
active, there is considerable interest in quantifying enzyme activity rather than protein levels11,12. Recently, Ivry 
and colleagues showed that activity from two aspartic acid proteases, gastricin and cathepsin E, is significantly 
increased in pre-malignant pancreatic cyst fluid when compared to benign cyst fluid13. Development of an assay 
to screen patient-derived cyst fluid for these protease activities has the potential to stratify patients for surgi-
cal intervention or surveillance. In addition, high levels of protease activity occurs in sputum of patients with 
chronic obstructive pulmonary disease14,15, cystic fibrosis16–18, and in non-healing wounds19,20. Many notable 
studies have been carried out to detect cathepsin-B and matrix metalloproteinases (MMPs), both involved in 
cancer and tumor metastasis, using nanoparticles21,22, fluorescent tomographic imaging23, and droplet microflu-
idics24. A nanoparticle-based approach25 was also used to detect the serine protease granzyme B, as a marker of 
early allograft rejection. Rapid and accurate quantification of proteases in biofluids such as plasma, urine, sputum, 
saliva, and wound fluid will allow clinicians to make important decisions about the treatment regimen.
To develop an activity-based protease biomarker of disease, it is essential to utilize a substrate that is efficiently 
cleaved by the protease of interest. Protease assays can be categorized as either homogenous or heterogeneous 
assays26. In a homogenous assay, the substrate and enzyme are both present in solution and generally utilize flu-
orescent or colorimetric peptide substrates that are illuminated upon protease cleavage27,28. In a heterogeneous 
assay, the enzyme is in solution while the substrate is immobilized. Heterogeneous protease assays have uti-
lized electrochemical detection29,30, surface plasmon resonance (SPR)31, surface-enhanced Raman spectroscopy 
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(SERS)32, ELISA, and liquid crystal technology33 and these assays have been developed for detection of enzyme 
activity for trypsin, caspase-3, and MMPs26.
In this study, we developed a heterogeneous protease assay that uses giant magnetoresistive spin-valve (GMR 
SV) sensors. These sensors transduce changes in the local magnetic field into electrical signals and have been used 
as the read head in hard disk drives34,35, current sensors36,37, magnetic memory38 and biosensors39,40. Their opera-
tion is rooted in quantum mechanics, exhibiting a phenomenon known as spin-dependent scattering41, wherein 
the device’s resistance is proportional to the magnetic field. These sensors are highly scalable, can be produced at 
low cost42, and manufactured in high volume. There are several advantages to using magnetic-based sensors for 
a protease assay over homogenous and other heterogeneous assay formats. First, clinical samples do not contain 
any magnetic content. Therefore, these samples have intrinsically low background signal, enabling high sensitiv-
ity. In comparison, optical assays face problems such as autofluorescence43 and label-bleaching44 that produce an 
undesired background signal. Second, the GMR SV sensors can be arrayed for multiplexed detection in a single 
assay without the need for optical scanning. Third, magnetic sensors are insensitive to the sample matrix, allowing 
them to be used with a wide variety of samples with minimal sample preparation45, making them convenient for 
use in point-of-care (POC) or point-of-use (POU) settings46. Lastly, the sensors continuously quantify the local 
magnetic field changes enabling real-time monitoring of the assay.
In previous applications of GMR SV biosensor technology, recruitment of magnetic nanoparticles (MNPs) 
to the surface via an antibody-antigen interaction was quantified in real-time47. However, in this study, we use 
this technology in reverse and without the use of antigens or antibodies. MNPs are first tethered to the magnetic 
sensor surface using a peptide, therefore creating an environment with high magnetoresistance (MR) signal. The 
peptide sequence is designed to be a substrate for the cysteine protease, papain. Upon addition of this enzyme, the 
peptide sequence is hydrolyzed, causing the MNPs to be released from the proximity of the sensor (Fig. 1). This 
results in a decrease in MR that can be monitored in real-time. When a fixed amount of peptide-MNP substrate 
is present, the release rate correlates with the protease concentration.
Results
Design of papain peptide substrate for heterogeneous assay. Papain is a well characterized cysteine 
protease related to several disease-associated proteases such as cathepsin K48 and cruzain49. This enzyme is opti-
mally active between pH 5.5 and 7.5 and irreversibly inactivated by the epoxide inhibitor, E-6450. We used this 
enzyme as a model system to test and validate our proof-of-concept heterogeneous GMR SV based protease assay. 
To identify a peptide sequence that is efficiently cleaved by papain, the enzyme was previously combined with 
an equimolar mixture of synthetic tetradecapeptides and cleavage products were quantified by mass spectrome-
try51. Using these data, we identified a tetradecapeptide substrate, KWLIHPTFSYnRWP, that was rapidly cleaved 
between S-Y and Y-n, where lowercase’n’ corresponds to the non-natural amino acid, norleucine. We synthesized 
the C-terminal region of this peptide that contained the sequence TFSYnRWP, corresponding to the amino acids 
that surround the cleavage sites. However, to make this sequence compatible with the heterogeneous assay format, 
Biotin-PEG36 and PEG12-Cys were included on the N-terminus and C-terminus, respectively (Fig. 2a). The func-
tion of the C-terminal cysteine residue is to facilitate immobilization of the Biotin-PEG36-TFSYnRWP-PEG12-Cys 
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Figure 1. Illustration of the magnetic detection scheme for protease activity. A biotinylated peptide is 
immobilized on the GMR SV sensors and placed in a magnetic field. Addition of streptavidin-coated MNPs 
causes an increase in magnetoresistance (MR) as they are orientated close to the sensor surface via the 
streptavidin-biotin interaction. When a biofluid sample containing a protease is added, cleavage of the peptide 
causes a time-dependent change in the MR as the MNPs are enzymatically released from the sensor surface.
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molecule (hereafter referred to as “peptide”) to a maleimide coated surface through a covalent thioether linkage. 
The function of the N-terminal biotin group is to bind a streptavidin coated reporter element such as streptavi-
din-marina blue (SA-MB) or streptavidin-coated MNP (SA-MNP).
immobilization of papain peptide substrate. The papain substrate (1–8 µM) was incubated for 2 hours 
in a microplate that was functionalized with BSA-maleimide. Unbound peptide was removed by washing and 
unreacted maleimide was blocked by the addition of free cysteine. The immobilized peptide containing an 
N-terminal biotin group was then quantified by labeling with SA-MB. We showed that the concentration of pep-
tide directly correlated with the fluorescent signal (Fig. 2b) and we chose a peptide concentration of 2 µM for the 
remainder of our studies as the signal-to-noise ratio (SNR) was greater than 10.
To ensure that labelling of the immobilized peptide occurs through direct interaction between biotin and 
streptavidin, a competition assay was performed using SA-MB and non-fluorescent streptavidin (Fig. 2c). When 
the immobilized papain substrate was first incubated with SA-MB and then with streptavidin, a strong fluores-
cent signal was detected (Fig. 2d). However, when the peptide substrate was first incubated with non-fluorescent 
streptavidin followed by SA-MB, no fluorescent signal was detected. These data show that the fluorescent signal 
generated using this heterogeneous assay is due to direct interaction between SA-MB and the immobilized biotin. 
In addition, these studies show that binding of the SA-MB complex is stable, as the fluorescent signal cannot be 
reduced even after 1-hour incubation with non-fluorescent streptavidin.
papain cleavage of immobilized peptide. After successful peptide loading, cleavage of this sequence 
by papain and release of SA-MB were evaluated. We incubated the immobilized peptide-SA-MB complex with 
20 nM of papain. At defined time intervals between 2.5 and 30 minutes, the enzyme activity was terminated by 
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Figure 2. (a) Design of a peptide substrate for a papain heterogeneous assay. Amino acids are listed using the 
standard three-letter code. (b) Standard curves for peptide loading capacity. A concentration of 2 µM was used 
for subsequent optical assays yielding an RFU reading of ~11,000. (c) Illustration of peptide immobilization 
scheme and streptavidin loading/blocking on polystyrene plates. (d) Bar graphs comparing the loading 
of fluorescent streptavidin Marina Blue (blue) and blocking with non-fluorescent streptavidin (orange) to 
immobilized peptide substrate. Error bars are ± 1σ.
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Figure 3. Time-dependent hydrolysis of immobilized peptide substrate by papain. No cleavage of the PEG 
linker was detected under the same conditions. Error bars are ±1σ.
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adding E-64 (Fig. 3). When all time points were acquired, the wells on the microplate were washed to remove 
peptide-SA-MB that had been enzymatically released from the surface. Any peptide-SA-MB that was still tethered 
to the surface was then quantified on the fluorescent microplate reader. Enzymatic activity by papain resulted a 
time-dependent decrease in fluorescence. After only 5 minutes, the fluorescent signal was reduced by ~50% and 
an additional 30% of peptide-SA-MB was removed over the next 15 minutes. The reaction was monitored for an 
additional 10 minutes (30 minutes total), however there was no further change in fluorescence during this time.
To ensure that the time-dependent reduction in fluorescence was due to the enzymatic activity of papain, a 
biotin-PEG75-thiol (hereafter known as “linker”) was included as a control. This linker lacks peptide bonds and 
therefore cannot be cleaved by papain; however, it can be immobilized to the plate surface via a covalent thioether 
linkage and bind to SA-MB. We show that papain was unable to reduce the fluorescence signal in wells that con-
tained this linker, therefore confirming that papain cleavage of the peptide causes the release of SA-MB in this 
heterogeneous assay.
immobilization of peptide substrate to GMR SV sensor. After verifying cleavage of the immobilized 
peptide by papain, the assay was translated to the GMR SV sensor array to demonstrate its potential for use in 
a wash-free, real-time, heterogeneous assay. The biochips consist of an 8×10 array of GMR SV sensors each 
measuring 90 µm2 and are coated with a 50 nm SiO2 passivation layer to protect them from corrosion47. The 
peptide was first conjugated to BSA-maleimide and this complex was nanospotted onto 25 sensors on the bio-
chip. The biochip was placed into a custom designed measurement station that can detect changes in MR (Fig. 
S1). SA-MNPs containing multiple Fe2O3 cores embedded in a dextran matrix were added. At this size scale, the 
MNPs are superparamagnetic, and we predicted that when orientated in close proximity to the sensor surface 
(<200 nm) an increase in MR will occur from the stray field generated by the MNPs.
SA-MNPs were added to the biochip and binding to the biotinylated peptide was monitored in real-time for 
32.5 minutes. The change in MR on the peptide spotted sensors (n = 16) was rapid in the initial 5-min interval 
(153.6 ppm/min) and then slowed over the remaining 25 min, from 31.0 ppm/min (between 5–10 min) to 1.34 
ppm/min (from 25–30 min) (Fig. 4a). Streptavidin was pre-incubated with 7 sensors on the biochip, prior to 
addition of SA-MNPs. Under these conditions, no change in MR occurred. These data show that the change in 
MR is due to direct binding of SA-MNPs to the immobilized peptide molecule. This assay format can clearly 
distinguish between bound and unbound SA-MNPs and therefore will enable us to perform protease-mediated 
MNP release assays.
Additional control conditions were also evaluated on the GMR SV sensors. We showed that the 
thiol-PEG75-biotin linker can be used to immobilize SA-MNPs to the biochip thereby providing us with 
a non-cleavable control for papain activity assays (Fig. 4b). After 40 minutes of SA-MNPs loading, the GMR 
SV sensors were incubated with excess biotin to block all available streptavidin molecules on the MNP surface. 
No MNPs were released from the surface indicating that there was strong affinity between the immobilized biotin 
and streptavidin on the MNPs (Fig. 4b). This blocking step was predicted to be important for downstream papain 
digestion assays, as SA-MNPs released by the action of the protease would be unable to re-attach to the surface.
GMR SV-based protease assays. A sensor array containing immobilized SA-MNPs was incubated with 20 nM 
of papain for 160 minutes and the MNPs were released from the surface in a time-dependent manner. After 160 min-
utes, 45% of the signal was reduced without any washing-steps being performed at pH 7.4 (Fig. 5a). Under the same 
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Figure 4. Real-time magnetometry loading data. (a) Loading of MNPs to immobilized peptides that were 
blocked with streptavidin (orange) or had no blocking (blue). (b) MNP loading to sensors via immobilized 
peptide (blue) and linker (green). Sensors lacking peptide and linker contained only BSA (red). Curves 
depicted are the mean signal of sensors and n corresponds to number of sensors that were functionalized. After 
40 minutes, all sensors were incubated with biotin to block all available streptavidin sites on MNPs. Error bars 
are ±1σ and ΔMR is the change in magnetoresistance from the initial value (MR0) in parts-per-million (ppm).
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conditions, sensors containing the non-cleavable linker sequence, showed only 6% reduction in MNP signal. These 
studies confirmed that protease activity can be measured in real-time using a wash-free GMR SV sensor assay.
For a magnetic nanosensor protease assay to have utility in a POC or POU setting, it should be able to rapidly 
quantify the protease concentration in a biofluid sample under a variety of assay conditions. Biofluids such as 
plasma, sputum, and wound fluid have a pH value close to neutral, and therefore the prototype assay described 
above is suitable for detecting protease activity under these conditions. However, other biofluids such as urine 
have a pH of 6.052, and it was unclear if the assay was compatible with these mildly acidic conditions. Papain is 
enzymatically active at pH 6.0 and therefore we evaluated the magnetic nanosensor assay in these conditions. 
We show that 57% of the MNPs are released from the sensor surface after 160 minutes incubation with 20 nM of 
papain at pH 6.0 while only 4% of the linker is released (Fig. 5a). Papain is more stable at acidic pH than at neutral 
pH and therefore the greater release of MNPs at pH 6.0 relative to pH 7.4 is likely due to increased stability of the 
enzyme in the acidic environment.
Next, we determined if the rate of MNP release correlates with enzyme concentration and if sufficient enzyme 
activity data can be generated within a shorter assay time. To do this, we assayed peptide and MNP coated bio-
chips with 4, 20, and 100 nM of papain for 10 minutes. The MNP release from the surface strongly correlates with 
the concentration of enzyme in the assay (Fig. 5b). Therefore, the rate of change in MR can be used to quantify the 
amount of papain in the assay. The minimum assay time where protease cleavage can be quantified corresponds to 
the time when the SNR is greater than 2. Under these conditions, 4 nM of papain was detected after 3.49 minutes 
incubation while 100 nM of papain can be quantified after 2.87 minutes incubation. These data validate the use of 
GMR SV sensors to rapidly quantify protease activity using a peptide release assay.
papain activity in urine. Urine is a commonly used biofluid for diagnosis of urinary tract infec-
tions caused by either bacteria or yeast53. Proteomic studies have shown that at least 41 proteases are present 
in urine from healthy individuals and fluorescent reporter peptides have been used to detect activity from 
these enzymes54. The most abundant urine proteases prefer cleaving one or two amino acids from the free 
N-terminus of proteins and peptides and therefore we predicted that these enzymes would not cleave the 
Biotin-PEG36-TFSYnRWP-PEG12-Cys peptide because the N-terminal threonine (T) residue is coupled to PEG36 
and therefore blocked. Urine also contains a broad acting cysteine protease inhibitor, cystatin C that potently 
inhibits papain. Using urine from three healthy individuals, cystatin C was inactivated with human cathepsin 
B. When these urine samples were then added to the GMR SV sensor containing the peptide and incubated for 
10 minutes, no significant reduction of MNPs was detected. This study shows that cathepsin B and the endoge-
nous urine proteases are unable to cleave the papain peptide substrate. Addition of 20 nM papain to these urine 
samples for 10 minutes resulted in a reduction in MR that was comparable to papain assayed in PBS (Fig. 5c). The 
average time for the SNR to be greater than 2 in these samples was 3.76 ± 0.25 minutes.
Discussion
The goal of this research is to demonstrate that GMR SV sensor-based detection can provide a POC or POU plat-
form to quantify proteases in patient samples. We show that the rate of MNP release by papain directly correlates 
with the concentration of papain in the assay. Therefore, this platform technology can utilize protease activity 
in a biological sample as a proxy for quantifying the concentration of the enzyme. Importantly, papain does not 
release MNPs when these particles are tethered to the sensor surface by a non-peptide linker. In addition, we 
show that a protease-containing sample such as urine, does not release MNPs when the peptide substrate was 
designed for cleavage by papain. However, upon addition of papain to the urine, the MNPs are released at a sim-
ilar rate to reactions that contain just papain in assay buffer.
In the described assay set-up, any peptide substrate that is cleaved by a protease-of-interest can be used in 
this magnetic sensor assay. The current GMR SV chips contain 80 sensors allowing for quantitation of multiple 
proteases in the same biofluid sample if they cleave different peptide substrates. Previous studies have shown that 
there is prevalence of proteinases secreted by pathogenic strains of Proteus bacteria and a significant increase 
in protease activity in urine of patients with urinary tract infections55,56. Our studies demonstrate the ability to 
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Figure 5. Measured real-time magnetometry papain digestion. (a) Normalized % reduction of peptide and 
linker sensors treated with 20 nM papain in pH 6.0 and pH 7.4 conditions. (b) Normalized % reduction data 
comparing the 4 nM (blue), 20 nM (yellow), and 100 nM (green) at pH 7.4 peptide treated sensors. Curves 
depicted are the mean signal of sensors that were functionalized. (c) Normalized % reduction of papain spiked 
urine samples and PBS. Error bars are ±1σ.
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potentially quantify various bacterial or fungal proteases present in urine of patients with urinary tract infections 
by developing a GMR SV sensor assay containing peptide substrates that are specifically cleaved by the microbial 
proteases. Using a papain concentration of 4 nM, we were able to detect protease activity in 3.5 min and therefore 
this assay has the potential to rapidly diagnose urinary tract infections, an important parameter for POC device 
usage. A magnetic detection strategy leverages the inherent negligible background signal in a biofluid which will 
allow us to achieve comparable sensitivity in serum, sputum, cyst fluid, semen, and wound fluid as urine.
The novel approach reported here has the potential to address several limitations posed by current protease 
sensors that have been described. Table 1 shows a comparison between this study and other protease detection 
strategies based on the buffer and/or biofluid tested, sensitivity, assay time, and sample preparation. Other detec-
tion methods such as electrochemical and SERS sensors have design requirements for the peptide substrate such 
that charged amino acids have to be included for optimal detection29,32. Peptides used in SPR sensors must have 
uncharged amino acids to minimize background signal due to their sensitivity to surface charge31. Fluorescent 
and colorimetric protease assays have been developed to detect protease activity in biofluids such as urine57,58, cyst 
fluid13, serum59,60, semen61, and sputum62 as well as used to discover protease inhibitors that have subsequently 
been developed into drugs63–67. However, many of these detection modalities require laboratory equipment, and 
thus are not suitable for POC and POU applications. GMR SV sensor arrays are compatible with complementary 
metal-oxide-semiconductor (CMOS) technology which can allow them to be inexpensively mass produced42 in a 
disposable format that is amenable to daily use, as well as integration into smartphone-based POC applications68–70. 
The sensor can also be produced in a pre-assembled manner by freeze-drying or lyophilizing the complexes such 
that it is in a “sample-to-answer” format without the need of additional detection reagents used in traditional ELISA 
assays. Real-time quantification of protease activity using GMR SV sensor-based detection has significant advan-
tages over current POC protease test kits that detect elevated protease activity in wound fluid71 or sputum72.
Peptide substrates that are designed to be cleaved by a target protease are often not selective for that enzyme. 
For example, Miller and colleagues showed that peptide substrates developed for select metalloproteinases, are 
efficiently cleaved by other proteases73. In addition, the peptide cleavage pattern generated by proteases in com-
plex biological samples can be difficult to deconvolute due to overlapping substrate specificity profiles of pro-
teases74. Therefore, it is essential to design peptide substrates that are selectively cleaved by the target proteases. 
Previously, we have identified peptide substrates that are efficiently cleaved by neutrophil elastase in neutro-
phil protein extracts75. Upon immunodepletion of this enzyme from the extract, these peptides were no longer 
cleaved, thereby validating the selectivity of the substrates for neutrophil elastase. When designing substrates for 
the GMR SV sensor assay, we will need to take the same approach and identify sequences that are cleaved by the 
target enzyme with little or no hydrolysis by other proteases in the sample.
The long-term goal of this research is to show that GMR SV sensor-based detection can provide a POC platform 
to detect various disease related proteases in patient samples. Future peptide sensors will explore the use of alter-
native peptide substrates that are selectively cleaved by either human or microbial protease targets. In addition, if 
multiple different peptide substrates provide a more accurate readout for a particular disease, then these substrates 
can be multiplexed on a single GMR SV chip to potentially quantify activity of multiple proteases simultaneously.
Methods
peptide/Linker immobilization on optical plates. Biotin-PEG36-Thr-Phe-Ser-Tyr-Nle-Arg-Trp-Pro-
PEG12-Cys (known as peptide) was synthesized by CPC Scientific and Biotin-PEG-SH (known as linker) was 
purchased from NANOCS. Peptide (2 µM) and linker (128 µM) were prepared in 0.1 M Na2HPO4, pH 7.4, 0.15 M 
NaCl, 10 mM EDTA (binding buffer) and added to maleimide activated wells of a 96-well plate (Pierce catalog 
#15153) and incubated for 2 h. All wells were then blocked with 57 µM Cysteine-HCl (Pierce) in D-PBS for 1 h 
followed by 1% BSA in D-PBS for 1 h. Wells were washed extensively with 0.1 M Na2HPO4, pH 7.2, 0.15 M NaCl, 
0.05% Tween-20 (buffer A) before and after each step. All steps were performed at room temperature.
Blocking with streptavidin on optical plates. After peptide/linker immobilization on maleimide coated 
wells, background fluorescence in each well was measured in a microplate reader with an excitation of 360 nm and 
Detection principle Protease Buffer/Biofluid Sensitivity Assay time Protease Enrichment
Sample 
Prep
Colorimetric71 Neutrophil elastase, MMPs wound fluid N/A 15 min No No
Colorimetric72 Neutrophil elastase sputum 338 nM 10 min Inhibitor capture Yes
Colorometric78 Trypsin carbonate buffer 400 pM 3.5 hr No No
Electrochemical29 Trypsin serum 600 pM 30 min No No
Electrochemical30 Trypsin PBS, artificial serum 20 fM 30 min Antibody capture No
Fluorescence13 Gastricsin Pancreatic cyst fluid 10 nM 1 hr No No
Fluorescence79 Prostate Specific Antigen seminal fluid 8 nM 15 min No No
Fluorescence62 Proteinase 3 sputum 260 pM 10 min Inhibitor capture Yes
Liquid crystal33 Trypsin, Chymotrypsin  PBS  40 pM, 4 pM  3 hr  No  No
SERS32 Trypsin PBS 1 nM 5 hr Gold nanoparticles No
Magnetic (this 
work) Papain PBS, urine 4 nM, 20 nM ~3.5 min No No
Table 1. Comparison between several protease-based assays developed and this work.
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an emission of 460 nm. 100 µL of 5 µg/mL streptavidin, Marina Blue conjugate (ThermoFisher Scientific #S11221) 
in D-PBS or 20 µg/mL streptavidin (ThermoFisher Scientific #21122) in D-PBS was added to wells and incubated 
for 1 h. Wells were washed extensively with buffer A and then incubated with 100 µL of 5 µg/mL streptavidin, 
Marina Blue conjugate, or 20 µg/mL of streptavidin for 1 h. After washing, 100 µL of D-PBS was added to each well 
and fluorescence was measured. All steps were performed at room temperature. The background fluorescence 
quantified in each well prior to addition of streptavidin was subtracted from the total fluorescence after addition 
of streptavidin.
time-dependent digestion on optical plates. 20 nM of papain in D-PBS, 2 mM DTT was added to each 
well and the reaction was incubated at room temperature. After defined time intervals of 0, 2.5, 5, 10, 15, 20, and 
30 mins, the reaction was stopped by addition of E-64 to a final concentration of 20 µM. Wells were washed exten-
sively with buffer A, hydrated with 100 µL of D-PBS, and fluorescence was measured as outlined above.
percent reduction calculations for optical assays. To calculate the reduction of fluorescent signal, the 
background fluorescence [A] is subtracted from both the pre-assay [B] and post-assay [C] fluorescence; divided 
by the difference between [A] and [B] and expressed as a percentage.
=
− − −
−
×
B A C A
B A
% reduction ( ) ( ) 100
Conjugation of maleimide activated BSA to peptide and linker. 20 µL of 1.33 mg/mL solution of 
BSA-maleimide (Imject Maleimide-Activated BSA, ThermoFisher Scientific #77115) in water, 56 µL of 273 µM 
peptide or 700 µM linker, and 24 µL of binding buffer were incubated for 24 h at 4 °C then dried in a vacuum cen-
trifuge. This complex was then dissolved in 10 µL of water.
chip functionalization. The chip was placed in a UV ozone cleaner for 10 minutes. A custom 3-D printed 
structure (printed using a Zortrax) with an attached silicone O-ring (High-Temperature High-Purity Silicone 
O-Rings for Tube Fittings with Straight-Thread Connection, McMaster-Carr #9396K422) was then screwed onto 
the chip to allow reagents to be pipetted onto the surface without leakage (Fig. S1a). The chip was washed with 
100 µL water and 1 µL of BSA (5%), BSA-peptide (1.33 mg/mL), 1.33 mg/mL BSA-Linker) was nanospotted onto 
the corners of the chip sensors with some separation. The chip was then incubated at 4 °C in a humidity chamber 
for 24 h, washed with water, and then blocked with 100 µL 5% BSA for 30 minutes.
Magnetic chip reader. The measurement setup consists of a computer, a power amplifier (PA, Kepco 
20-5D), a Helmholtz coil and custom readout electronics76. The GMR SV sensor chip, which has 80 individually 
addressable sensors with a nominal resistance of 1.3 kΩ and an MR ratio of 10.6%, was placed firmly inside of 
the Helmholtz coil using a custom designed sensor holder (Fig. S1b). A double modulation readout scheme was 
used to reject 1/f noise from both the sensors and electronics, and temperature compensation technique was 
used to reduce temperature drift77. The computer digitally adjusted the frequencies and amplitudes of sensor bias 
voltage and magnetic field through a National Instruments data acquisition card (DAQ, NI PCIe-6351) and a 
LabVIEW graphical user interface (GUI). Specifically, the PA controlled by the computer provided current into 
the Helmholtz coil, which offers homogenous magnetic field (23–34 Oerms based on the sensor MR) for the sensor 
chip. The readout electronics contain 8× transimpedance amplifiers to convert the currents to voltages that was 
quantized by the DAQ. Time-multiplexing was applied to read out the entire 8 × 10 sensor array with a 10 second 
update rate.
Magnetic sensor assays. 1 µL of 1 mg/mL streptavidin was nanospotted onto sensors containing BSA, 
BSA-peptide, or BSA-linker and incubated for 30 minutes followed by washing with water and then PBS. The 
chip was then connected to the electromagnet measurement station (Fig. S1b). Sensors were loaded with 60 µL of 
50 nm magnetic nanoparticles coated with streptavidin (Miltenyi Biotec #130-048-101) for 35 minutes followed 
by five washes with 100 µL buffer A. 100 µL of 1 mM biotin (Fisher Scientific, 15486) was added for 10 minutes 
followed by five washes with 100 µL buffer A. 100 µL of papain in D-PBS, pH 7.4 or D-PBS, pH 6.0 (adjusted to 
pH 6.0 with citric acid) was added and incubated for up to 200 minutes. To stop the assay, the sensor was washed 
five times in buffer A.
papain activity in urine. Urine from healthy donors was purchased from Innovative Research, Novi, 
Michigan (IRHUURES50ML). 97 µL of urine was incubated with 1 µL of human cathepsin B (R&D Systems, 
953-CY-010) and 1 µL of DTT for 15 minutes to inactivate the urine cysteine protease inhibitor, cystatin C. The 
cystatin C-inactivated urine was then added to the sensor well and magnetoresistance was evaluated for 20 min-
utes. 1 µL of papain was then added to the urine and MR signal was evaluated for 100 minutes. The final concen-
tration of cathepsin B, DTT, and papain in the urine assay was 10 µM, 2 mM, and 10 nM, respectively.
Magnetic assay time of detection of papain activity calculations. The signal-to-noise ratio (SNR) 
for each time point was determined by calculating the difference of mean signal (S) for the peptide and linker 
sensors divided by the noise which is equal to square root of the sum of variances (σ2) of peptide and linker data.
σ σ
=
−
+
SNR
S Speptide linker
peptide linker
2 2
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